<DOC>
	<DOCNO>NCT01901198</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose Chinese healthy volunteer .</brief_summary>
	<brief_title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study Chinese Healthy Volunteers</brief_title>
	<detailed_description>This open-label study conduct single site China characterize PK/PD profile , safety tolerability Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein healthy subject . Subjects receive single dose Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein active comparator Pegasys Day 0 . The total duration study participation 6 week subject . Subjects complete follow-up visit Day 28 dosing .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Must healthy male females 18 45 year old , inclusive Must body mass index ( BMI ) 19 25 kg/m2 , inclusive , minimum body weight 50.0 kg History clinically significant laboratory abnormality , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease Female subject pregnant breastfeed Any previous treatment Human Albumin Interferon fusion protein Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>